Autopsy report · NCT01934894

Cabazitaxel Plus Lapatinib as Therapy for HER2-Positive Metastatic Breast Cancer Patients With Intracranial Metastases

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Study was terminated due to lack of significant signal of efficacy”

The sponsor’s own words in the registry.

Life of this trial

Registered 9 months before it started.
Ran for about 2 years 11 months before it stopped.
11 participants enrolled.
Results were posted on the registry 2 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2
Sponsor: SCRI Development Innovations, LLC
Sponsor type: University, hospital or other
Conditions: Metastatic Breast Cancer With Intracranial Metastases
Interventions: cabazitaxel; lapatinib
Participants: 11
Sites: 4
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.